Evidence map›Paper›PMID 25375803›Full record

ArticlePloS one2014

Clinicopathologic characteristics of typical medullary breast carcinoma: a retrospective study of 117 cases.

Zhaohui Chu, Hao Lin, Xiaohua Liang, Ruofan Huang, Qiong Zhan, Jingwei Jiang, Xinli Zhou

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Characteristics of Special Type Breast Tumors in Our Center.European journal of breast health · 2018
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Zhaohui ChuDepartment of Oncology, Huashan Hospital, Fudan University, Shanghai, China, 200040; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China, 200032.
Hao LinDepartment of Oncology, Huashan Hospital, Fudan University, Shanghai, China, 200040; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China, 200032.
Xiaohua LiangDepartment of Oncology, Huashan Hospital, Fudan University, Shanghai, China, 200040; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China, 200032.
Ruofan HuangDepartment of Oncology, Huashan Hospital, Fudan University, Shanghai, China, 200040; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China, 200032.
Qiong ZhanDepartment of Oncology, Huashan Hospital, Fudan University, Shanghai, China, 200040; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China, 200032.
Jingwei JiangDepartment of Oncology, Huashan Hospital, Fudan University, Shanghai, China, 200040; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China, 200032.
Xinli ZhouDepartment of Oncology, Huashan Hospital, Fudan University, Shanghai, China, 200040; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China, 200032.
Fudan University · CNHuashan Hospital · CNShanghai Medical College of Fudan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis study analyzed the clinicopathologic characteristics of typical medullary breast carcinoma (TMBC) in a cohort of Chinese patients.

methodsWe conducted a retrospective review of clinical data including general information, pathologic results, treatment regimens, and patient survival in cases of TMBC diagnosed between February 2004 and April 2011.

resultsA total of 117 patients were enrolled, with a median age of 52 years (range, 28∼92 years). Stage I and II disease accounted for 31.6% and 61.6% of the cases, respectively. Hormonal receptor negative disease (estrogen receptor negative, 68.4%; progestogen receptor negative, 86.3%) was more prevalent in this population. Human epidermal growth factor receptor-2 (HER-2) positivity was 20.5%, while equivocal and HER-2 negative cases represented 16.2% and 63.2% of the cohort. The triple-negative, luminal, and HER-2 overexpressing subtypes constituted 44.4%, 31.6%, and 15.4% of the cases, respectively. The various TMBC subtypes showed no differences regarding tumor size, rates of lymph node(s) metastasis, TNM staging, treatment regimens, and 2-year recurrence rates. However, patients with triple-negative disease were more likely to be younger, when compared to those with luminal disease (P = 0.002). At a median follow-up of 56 months (range, 2-112 months), the 2-year disease-free survival and overall survival rates were 99.1% and 98.2%, respectively.

conclusionEarly stage disease dominated the study cohort, and at two years after surgery, recurrence was extremely low. The heterogeneity of molecular subtypes was clearly shown, and no apparent differences were found among the clinicopathologic characteristics of the triple-negative, luminal, and HER-2 overexpressing subtypes.

Indexed as

AdultAgedAged, 80 and overBreast NeoplasmsCarcinoma, MedullaryDisease-Free SurvivalErb-b2 Receptor Tyrosine KinasesFemaleFollow-Up StudiesHumansMiddle AgedNeoplasm Recurrence, LocalPrognosisReceptors, EstrogenReceptors, ProgesteroneRetrospective StudiesERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, Progesterone

Identifiers

PMID25375803
PMCPMC4222917
OpenAlexW2045396550

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.